

## Product Information

# 3,3'-Diaminobenzidine (DAB) Enhanced Liquid Substrate System

Tetrahydrochloride, for Membrane Applications

**D6815**

## Product Description

Diaminobenzidine (DAB) is used in many applications to visualize peroxidase activity.<sup>1-6</sup> The DAB Enhanced Liquid Substrate System is for use in membrane ELISA procedures as a precipitating substrate for the detection of peroxidase activity. DAB is the immunohistology substrate of choice, because it produces an intense brown stain that is easily observed. The end product is resistant to alcohol. Thus, various counterstains and mounting media in alcoholic solutions can be used with the DAB Liquid Substrate System.

The DAB Enhanced Liquid Substrate System is supplied as two reagents, the buffer and the chromogen, which are mixed together immediately prior to use. The DAB Liquid Substrate System provides all the chromogen and buffer/peroxide solutions that are needed to produce a fast and convenient DAB substrate solution.

Several publications<sup>7-10</sup> and dissertations<sup>11-13</sup> have cited use of product D6815 in their research protocols.

## Storage/Stability

The DAB buffer and DAB chromogen solutions are stable for up to 18 months when stored at 2-8 °C in the original containers.

After combining the two components, the resulting reagent is stable for:

- 2 to 4 hours at room temperature
- up to 8 hours at 2-8 °C

During these time periods, the 1× reagent may develop a darker color. However, the reagent performance will not be affected.

## Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Components

This DAB Liquid Substrate System product consists of the following reagents:

- DAB Liquid Buffer Solution A (Component Number D5940): 4 × 100 mL
- DAB Liquid Chromogen Solution B (Component Number D5815): 15 mL

## Reagents and Equipment Required but Not Provided

- Test tubes

## Procedure

1. Add one drop of the DAB Liquid Chromogen Solution B (approximately 30 µL) to a test tube. Dilute with 1 mL of DAB Liquid Buffer Solution A. Mix well. Larger quantities can be made using the same ratio of concentrate to buffer.
2. Apply a sufficient volume of the prepared DAB reagent solution to cover the membrane completely.
3. Incubate for 5 to 30 minutes. It may be useful to monitor the development of the reaction product to prevent overstaining.
4. Stop the reaction by gently rinsing the membrane in 2 to 3 changes of distilled water.
5. Allow the membrane to dry for appropriate results.

- Dilution of the DAB Liquid reagents is **not recommended**. To reduce the intensity of a reaction, it is recommended that the antibodies or conjugates be diluted, or the reaction time be reduced.

## Troubleshooting

### Background too high

- Decrease the staining time.
- Titer the conjugate to optimize working dilution.

### No color develops or color is too faint

- Adjust the concentration of the primary antibody.
- Adjust the concentration of the secondary antibody.
- Determine if the enzyme conjugate is active.
- Consider using an amplifying system such as avidin-biotin.
- Increase the staining time.

## References

- Nakane, P.K., and Pierce, G.B., Jr., *J. Histochem. Cytochem.*, **14(12)**, 929-931 (1966).
- Trojanowski, J.Q. *et al.*, *J. Histochem. Cytochem.*, **31**, 1217-1223 (1983).
- DeJong, A.S.H. *et al.*, *Histochem. J.*, **17(10)**, 1119-1130 (1985).
- Chu, N.M. *et al.*, *J. Histochem. Cytochem.*, **37(2)**, 257-263 (1989).
- Merenthaler, I. *et al.*, "Silver Intensification in Immunocytochemistry", in *Techniques in Immunocytochemistry* (Bullock, G., and Petrusz, P., eds.). Academic Press Ltd. (San Diego, CA), pp. 217-252 (1989).
- Hsu, S., and Soban, E., *J. Histochem. Cytochem.*, **30(10)**, 1079-1082 (1982).
- Polcyn, W., *Acta Biochim. Pol.*, **55(4)**, 761-766 (2008).
- Teng, R. *et al.*, *Basic Res. Cardiol.*, **106(3)**, 343-354 (2011).
- Nieves, E. *et al.*, *J. Vector Borne Dis.*, **49(1)**, 8-14 (2012).
- Mittereder, N. *et al.*, *J. Immunol.*, **197(2)**, 491-503 (2016).
- De Vita, Serena, "Modelling Down syndrome leukaemia using transchromosomal ES cell lines". Queen Mary University of London, Ph.D. dissertation, p. 82 (2009).
- Jorge, Francis Mark, "The potential pathogenicity of *Dolosigranulum pigrum* in multiple sclerosis, and the occurrence of the organism in the upper respiratory tract". University of Portsmouth, Ph.D. dissertation, pp. 61, 141 (2014).
- Machado e Silva, Lisete, "Structural analysis of glycans and development of microarrays from *Helicobacter pylori* cell surface glycome". Universidade de Aviero, Ph.D. dissertation, p. 78 (2014).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

### Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

### Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

### Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

D6815dat Rev 03/22 FEB,GCY,MAM

